Direct Observation of Nanostructures during Aqueous Dissolution of Polymer/Drug Particles

Ralm G. Ricarte, Ziang Li, Lindsay M. Johnson, Jeffrey M. Ting, Theresa M. Reineke, Frank S. Bates, Marc A. Hillmyer, Timothy P. Lodge

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

To elucidate the aqueous solubility enhancement mechanism of solid dispersions (SDs), metastable blends of an active pharmaceutical ingredient (API) and a polymer excipient, we investigated the dissolution of hydroxypropyl methylcellulose acetate succinate (HPMCAS) SDs in phosphate buffered saline (PBS). Two hydrophobic active pharmaceutical agents, phenytoin and probucol, were employed at loadings of 10, 25, and 50 wt % relative to polymer. Light scattering measurements of HPMCAS solutions showed that the polymer itself formed a mixture of ∼10 and ∼100 nm sized structures (attributed to linear and covalently coupled polymer chains, respectively) in both tetrahydrofuran and PBS. The measurements also revealed that PBS is a poor solvent for HPMCAS at and below 37 °C, potentially inducing the polymer to associate with itself or other hydrophobic species in solution. During in vitro dissolution of HPMCAS SDs-containing either phenytoin or probucol as the API-the polymer and hydrophobic drug formed <100 nm amorphous nanoparticles. Using a combination of cryogenic transmission electron microscopy (both imaging and electron diffraction) and small-angle X-ray scattering, a direct correlation between SD dissolution profiles and nanostructure evolution was discovered for both drugs. In other words, the drug that is measured in the dissolution assay is retained in the supernatant in the form of nanoparticles. The size, shape, and lifespan of the nanoparticles were a function of drug identity, loading, and targeted concentration. These findings confirm the importance of persistent nanostructures to SD dissolution and particularly to maintenance of supersaturation.

Original languageEnglish (US)
Pages (from-to)3143-3152
Number of pages10
JournalMacromolecules
Volume50
Issue number8
DOIs
StatePublished - Apr 25 2017

Fingerprint

hydroxypropylmethylcellulose acetate succinate
Nanostructures
Dispersions
Polymers
Dissolution
Pharmaceutical Preparations
Drug products
Phosphates
Probucol
Nanoparticles
Phenytoin
Supersaturation
X ray scattering
Excipients
Electron diffraction
Light scattering
Cryogenics
Assays
Solubility
Transmission electron microscopy

How much support was provided by MRSEC?

  • Shared

Reporting period for MRSEC

  • Period 4

Cite this

Direct Observation of Nanostructures during Aqueous Dissolution of Polymer/Drug Particles. / Ricarte, Ralm G.; Li, Ziang; Johnson, Lindsay M.; Ting, Jeffrey M.; Reineke, Theresa M.; Bates, Frank S.; Hillmyer, Marc A.; Lodge, Timothy P.

In: Macromolecules, Vol. 50, No. 8, 25.04.2017, p. 3143-3152.

Research output: Contribution to journalArticle

@article{5a0333504d21457db63e1e9a519213f6,
title = "Direct Observation of Nanostructures during Aqueous Dissolution of Polymer/Drug Particles",
abstract = "To elucidate the aqueous solubility enhancement mechanism of solid dispersions (SDs), metastable blends of an active pharmaceutical ingredient (API) and a polymer excipient, we investigated the dissolution of hydroxypropyl methylcellulose acetate succinate (HPMCAS) SDs in phosphate buffered saline (PBS). Two hydrophobic active pharmaceutical agents, phenytoin and probucol, were employed at loadings of 10, 25, and 50 wt {\%} relative to polymer. Light scattering measurements of HPMCAS solutions showed that the polymer itself formed a mixture of ∼10 and ∼100 nm sized structures (attributed to linear and covalently coupled polymer chains, respectively) in both tetrahydrofuran and PBS. The measurements also revealed that PBS is a poor solvent for HPMCAS at and below 37 °C, potentially inducing the polymer to associate with itself or other hydrophobic species in solution. During in vitro dissolution of HPMCAS SDs-containing either phenytoin or probucol as the API-the polymer and hydrophobic drug formed <100 nm amorphous nanoparticles. Using a combination of cryogenic transmission electron microscopy (both imaging and electron diffraction) and small-angle X-ray scattering, a direct correlation between SD dissolution profiles and nanostructure evolution was discovered for both drugs. In other words, the drug that is measured in the dissolution assay is retained in the supernatant in the form of nanoparticles. The size, shape, and lifespan of the nanoparticles were a function of drug identity, loading, and targeted concentration. These findings confirm the importance of persistent nanostructures to SD dissolution and particularly to maintenance of supersaturation.",
author = "Ricarte, {Ralm G.} and Ziang Li and Johnson, {Lindsay M.} and Ting, {Jeffrey M.} and Reineke, {Theresa M.} and Bates, {Frank S.} and Hillmyer, {Marc A.} and Lodge, {Timothy P.}",
year = "2017",
month = "4",
day = "25",
doi = "10.1021/acs.macromol.7b00372",
language = "English (US)",
volume = "50",
pages = "3143--3152",
journal = "Macromolecules",
issn = "0024-9297",
publisher = "American Chemical Society",
number = "8",

}

TY - JOUR

T1 - Direct Observation of Nanostructures during Aqueous Dissolution of Polymer/Drug Particles

AU - Ricarte, Ralm G.

AU - Li, Ziang

AU - Johnson, Lindsay M.

AU - Ting, Jeffrey M.

AU - Reineke, Theresa M.

AU - Bates, Frank S.

AU - Hillmyer, Marc A.

AU - Lodge, Timothy P.

PY - 2017/4/25

Y1 - 2017/4/25

N2 - To elucidate the aqueous solubility enhancement mechanism of solid dispersions (SDs), metastable blends of an active pharmaceutical ingredient (API) and a polymer excipient, we investigated the dissolution of hydroxypropyl methylcellulose acetate succinate (HPMCAS) SDs in phosphate buffered saline (PBS). Two hydrophobic active pharmaceutical agents, phenytoin and probucol, were employed at loadings of 10, 25, and 50 wt % relative to polymer. Light scattering measurements of HPMCAS solutions showed that the polymer itself formed a mixture of ∼10 and ∼100 nm sized structures (attributed to linear and covalently coupled polymer chains, respectively) in both tetrahydrofuran and PBS. The measurements also revealed that PBS is a poor solvent for HPMCAS at and below 37 °C, potentially inducing the polymer to associate with itself or other hydrophobic species in solution. During in vitro dissolution of HPMCAS SDs-containing either phenytoin or probucol as the API-the polymer and hydrophobic drug formed <100 nm amorphous nanoparticles. Using a combination of cryogenic transmission electron microscopy (both imaging and electron diffraction) and small-angle X-ray scattering, a direct correlation between SD dissolution profiles and nanostructure evolution was discovered for both drugs. In other words, the drug that is measured in the dissolution assay is retained in the supernatant in the form of nanoparticles. The size, shape, and lifespan of the nanoparticles were a function of drug identity, loading, and targeted concentration. These findings confirm the importance of persistent nanostructures to SD dissolution and particularly to maintenance of supersaturation.

AB - To elucidate the aqueous solubility enhancement mechanism of solid dispersions (SDs), metastable blends of an active pharmaceutical ingredient (API) and a polymer excipient, we investigated the dissolution of hydroxypropyl methylcellulose acetate succinate (HPMCAS) SDs in phosphate buffered saline (PBS). Two hydrophobic active pharmaceutical agents, phenytoin and probucol, were employed at loadings of 10, 25, and 50 wt % relative to polymer. Light scattering measurements of HPMCAS solutions showed that the polymer itself formed a mixture of ∼10 and ∼100 nm sized structures (attributed to linear and covalently coupled polymer chains, respectively) in both tetrahydrofuran and PBS. The measurements also revealed that PBS is a poor solvent for HPMCAS at and below 37 °C, potentially inducing the polymer to associate with itself or other hydrophobic species in solution. During in vitro dissolution of HPMCAS SDs-containing either phenytoin or probucol as the API-the polymer and hydrophobic drug formed <100 nm amorphous nanoparticles. Using a combination of cryogenic transmission electron microscopy (both imaging and electron diffraction) and small-angle X-ray scattering, a direct correlation between SD dissolution profiles and nanostructure evolution was discovered for both drugs. In other words, the drug that is measured in the dissolution assay is retained in the supernatant in the form of nanoparticles. The size, shape, and lifespan of the nanoparticles were a function of drug identity, loading, and targeted concentration. These findings confirm the importance of persistent nanostructures to SD dissolution and particularly to maintenance of supersaturation.

UR - http://www.scopus.com/inward/record.url?scp=85018656042&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018656042&partnerID=8YFLogxK

U2 - 10.1021/acs.macromol.7b00372

DO - 10.1021/acs.macromol.7b00372

M3 - Article

AN - SCOPUS:85018656042

VL - 50

SP - 3143

EP - 3152

JO - Macromolecules

JF - Macromolecules

SN - 0024-9297

IS - 8

ER -